United Therapeutics (UTHR) Non-Current Debt (2010 - 2024)

United Therapeutics (UTHR) has 13 years of Non-Current Debt data on file, last reported at $100.0 million in Q2 2024.

• For the quarter ending Q2 2024, Non-Current Debt fell 87.5% year-over-year to $100.0 million; the trailing twelve-month figure through Jun 2024 stood at $100.0 million (down 87.5% YoY), and the FY2023 full-year result was $300.0 million, down 62.5% from the prior year.
• Non-Current Debt fell to $100.0 million in Q2 2024, from $200.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $800.0 million in Q1 2020 to a low of $100.0 million in Q2 2024.
• A 5-year average of $683.3 million and a median of $800.0 million in 2020 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 33.33% in 2020 and tumbled 87.5% in 2024, its largest moves.
• Tracing UTHR's Non-Current Debt over 5 years: stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then tumbled by 62.5% to $300.0 million in 2023, then tumbled by 66.67% to $100.0 million in 2024.
• Business Quant data shows UTHR's Non-Current Debt at $100.0 million in Q2 2024, $200.0 million in Q1 2024, and $300.0 million in Q4 2023.